504 related articles for article (PubMed ID: 15818508)
1. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
2. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
7. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Wright MA; Morrison G; Lin P; Leonard GD; Nguyen D; Guo X; Szabo E; Hopkins JL; Leguizamo JP; Harold N; Fioravanti S; Schuler B; Monahan BP; Saif MW; Quinn MG; Pang J; Grem JL
Clin Cancer Res; 2005 Jun; 11(11):4144-50. PubMed ID: 15930350
[TBL] [Abstract][Full Text] [Related]
8. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Mavroudis D; Kalbakis K; Kotsakis A; Vardakis N; Koukourakis M; Romanos J; Georgoulias V
Oncology; 2001; 60(3):207-13. PubMed ID: 11340371
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Goldberg RM; Kaufmann SH; Atherton P; Sloan JA; Adjei AA; Pitot HC; Alberts SR; Rubin J; Miller LL; Erlichman C
Ann Oncol; 2002 Oct; 13(10):1674-80. PubMed ID: 12377659
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Ducreux M; Ychou M; Seitz JF; Bonnay M; Bexon A; Armand JP; Mahjoubi M; Méry-Mignard D; Rougier P
J Clin Oncol; 1999 Sep; 17(9):2901-8. PubMed ID: 10561369
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
[TBL] [Abstract][Full Text] [Related]
15. Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.
Bonetti A; Zaninelli M; Durante E; Fraccon AP; Franceschi T; Pasini F; Zustovich F; Brienza S
Tumori; 2006; 92(5):389-95. PubMed ID: 17168430
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Kambe M; Kikuchi H; Gamo M; Yoshioka T; Ohashi Y; Kanamaru R
Int J Clin Oncol; 2012 Apr; 17(2):150-4. PubMed ID: 21786211
[TBL] [Abstract][Full Text] [Related]
17. S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Ramnath N; Khushalani N; Toth K; Litwin AM; Intengan ME; Slocum HK; Pendyala L; Smith PF; Stewart CC; Hoffman JL; Javle MM; Berdzik J; Creaven PJ; Rustum YM
Cancer Chemother Pharmacol; 2005 Nov; 56(5):447-54. PubMed ID: 15947933
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
